These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9600792)

  • 21. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.
    Stepan JJ; Burckhardt P; Hána V
    Bone; 2003 Oct; 33(4):589-96. PubMed ID: 14555263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
    Delmas PD; Recker RR; Chesnut CH; Skag A; Stakkestad JA; Emkey R; Gilbride J; Schimmer RC; Christiansen C
    Osteoporos Int; 2004 Oct; 15(10):792-8. PubMed ID: 15071723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Schlosser K; Scigalla P
    Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Relevance of Osteoclastic and Osteoblastic Activity Markers Follow-Up in Patients on Antiresorptive Osteoporosis Treatment.
    Smilic TN; Novakovic TR; Markovic-Jovanovic SR; Smilic LLJ; Mitic JS; Radunovic ML
    J Clin Densitom; 2018; 21(3):322-328. PubMed ID: 29103946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
    J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High bone turnover is associated with low bone mass in both pre- and postmenopausal women.
    Ravn P; Fledelius C; Rosenquist C; Overgaard K; Christiansen C
    Bone; 1996 Sep; 19(3):291-8. PubMed ID: 8873970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N; Silverman SL; Simonelli C; Santiago N; Kohles JD; Dasic G; Sunyecz JA
    Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
    Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.
    Christiansen C; Tankó LB; Warming L; Moelgaard A; Christgau S; Qvist P; Baumann M; Wieczorek L; Hoyle N
    Osteoporos Int; 2003 Jul; 14(7):609-13. PubMed ID: 12830369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.